AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32711674 — intervention group
Group type: EXPERIMENTAL
Intervention: SENTIA (new measuring instrument for assessing suicidal behavior)
Number of subjects: 1790
Study 32711674 — intervention group
Group type: EXPERIMENTAL
Intervention: SENTIA
Number of subjects: 1790
Study 35294813 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.45 mg
Number of subjects: 288
Study 35294813 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.30 mg
Number of subjects: 288
Study 35294813 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.15 mg
Number of subjects: 288
Study 35294813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 34269747 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticospinal tract fractional anisotropy asymmetry (FAasym)
Number of subjects: 0
Study 34269747 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate LASSO model including baseline CST FAasym, age, and UE Fugl‐Meyer
Number of subjects: 0
Study 35429404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 456
Study 35429404 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 456
Study 35429404 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 456
Study 33764084 — intervention group
Group type: EXPERIMENTAL
Intervention: OurRelationship (OR) program
Number of subjects: 934
Study 33764084 — intervention group
Group type: EXPERIMENTAL
Intervention: ePREP program
Number of subjects: 934
Study 33764084 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 934
Study 32254003 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI‐psych) score
Number of subjects: 1660
Study 36256856 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behaviour Game (GBG)
Number of subjects: 731
Study 36256856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 731
Study 34275690 — intervention group
Group type: EXPERIMENTAL
Intervention: Primarily Joint
Number of subjects: 302
Study 34275690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed MoU
Number of subjects: 302
Study 34275690 — intervention group
Group type: EXPERIMENTAL
Intervention: Primarily Pipe
Number of subjects: 302
Study 34275690 — intervention group
Group type: EXPERIMENTAL
Intervention: Primarily Blunt
Number of subjects: 302
Study 35401282 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT rs4680 met allele
Number of subjects: 212
Study 35401282 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory GWAS for change in pain frequency
Number of subjects: 212
Study 35401282 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory GWAS for change in pain severity
Number of subjects: 212
Study 33831369 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 M DMSO cryopreserved testicular cells
Number of subjects: 0
Study 33831369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal transplantation of recovered cells
Number of subjects: 0
Study 33831369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm collected from recipients
Number of subjects: 0
Study 35191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental bibliotherapy using 54 selected materials from the DBMD for 6 weeks
Number of subjects: 64
Study 35191766 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental bibliotherapy
Number of subjects: 64
Study 33663489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on multivariable model including type 2 diabetes mellitus (T2DM), microangiopathy, history of congestive heart failure (CHF), history of hypertension, diastolic blood pressure (DBP), urine output, Glasgow coma scale (GCS), and respiratory rate (RR).
Number of subjects: 760
Study 35724304 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1536
Study 32549142 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program promoting healthy eating habits for six months
Number of subjects: 0
Study 32549142 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35397664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib (oral poly(ADP‐ribose) polymerase inhibitor)
Number of subjects: 458
Study 35397664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 458
Study 32210349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-PA-HCP in bouillon without inhibitory matrix
Number of subjects: 22
Study 32210349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-PA-HCP in bouillon with inhibitory matrix
Number of subjects: 22
Study 32210349 — intervention group
Group type: COMPARATOR
Intervention: FeSO4 in bouillon
Number of subjects: 22
Study 32210349 — intervention group
Group type: COMPARATOR
Intervention: FePP in bouillon
Number of subjects: 22
Study 32210349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-PA-HCP with inhibitory meal
Number of subjects: 22
Study 32210349 — intervention group
Group type: COMPARATOR
Intervention: FePP with inhibitory meal
Number of subjects: 22
Study 33450335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 313
Study 33450335 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 313
Study 33450335 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe AKI (overall)
Number of subjects: 313
Study 33225663 — intervention group
Group type: COMPARATOR
Intervention: Intralesional sodium Stibogluconate (1-5 ml depending on lesion size, 100 mg/ml)
Number of subjects: 164
Study 33225663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of oral Allopurinol (20 mg/kg/day in divided doses) and intralesional sodium Stibogluconate (1-5 ml depending on lesion size, 100 mg/ml)
Number of subjects: 164
Study 34897499 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + MTX ≤8 mg/week
Number of subjects: 401
Study 34897499 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept + MTX >8 mg/week
Number of subjects: 401
Study 34897499 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX ≤8 mg/week
Number of subjects: 401
Study 34897499 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX >8 mg/week
Number of subjects: 401
Study 34139861 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital heart disease (CHD) patients
Number of subjects: 88700
Study 34139861 — intervention group
Group type: COMPARATOR
Intervention: Matched controls without CHD
Number of subjects: 88700
Study 33666187 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1000 mg thrice daily for 7 days
Number of subjects: 60
Study 33666187 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir 500 mg thrice daily for 7 days
Number of subjects: 60
Study 35275761 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 16
Study 35275761 — intervention group
Group type: COMPARATOR
Intervention: Baseline (without CPAP)
Number of subjects: 16
Study 34508090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharm-TCR (low-carbohydrate <50 g, energy-restricted diet 850-1100 kcal/day)
Number of subjects: 188
Study 34508090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharm-TCR
Number of subjects: 188
Study 34508090 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 188
Study 32223113 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3604
Study 32223113 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3604
Study 35595373 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Specialty Palliative Care (SPC)
Number of subjects: 500
Study 35595373 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study 32514677 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises in addition to conventional physical therapy (PT) for 3 months
Number of subjects: 33
Study 32514677 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (PT)
Number of subjects: 33
Study 32514677 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises in addition to conventional physical therapy (PT)
Number of subjects: 33
Study 34729862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen therapy (HFNC)
Number of subjects: 24
Study 34729862 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask (VM) therapy
Number of subjects: 24
Study 33892331 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat attenders
Number of subjects: 42
Study 33892331 — intervention group
Group type: COMPARATOR
Intervention: Single attenders
Number of subjects: 42
Study 32245745 — intervention group
Group type: EXPERIMENTAL
Intervention: Dresden bone-anchored expander
Number of subjects: 29
Study 32245745 — intervention group
Group type: COMPARATOR
Intervention: Conventional hyrax expander
Number of subjects: 29
Study 35073825 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training prescribed at 80% of 6MWT average speed
Number of subjects: 11
Study 35320692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten20 Conductive PasteTM with Tensive® adhesive gel and hydrogel electrodes on hairless locations (Group 2)
Number of subjects: 79
Study 35320692 — intervention group
Group type: COMPARATOR
Intervention: Ten20 Conductive PasteTM with Tensive® adhesive gel (Group 1)
Number of subjects: 79
Study 35320692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 32549168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bhramari pranayama (Bhr.P)
Number of subjects: 520
Study 32549168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 520
Study 35576721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic tumour features (imaging biomarkers)
Number of subjects: 0
Study 34403795 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the American College of Surgeons National Surgical Quality Improvement Program (NSQIP)
Number of subjects: 0
Study 33469276 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact weight-bearing/high-intensity/velocity resistance training (EG: n=27) exercising three times a week
Number of subjects: 54
Study 33469276 — intervention group
Group type: COMPARATOR
Intervention: Attendance control group (CG: n=27) performing low-intensity exercise once a week
Number of subjects: 54
Study 33469276 — intervention group
Group type: EXPERIMENTAL
Intervention: High impact weight-bearing/high-intensity/velocity resistance training (EG: n=27)
Number of subjects: 54
Study 33469276 — intervention group
Group type: COMPARATOR
Intervention: Attendance control group (CG: n=27)
Number of subjects: 54
Study 32246302 — intervention group
Group type: EXPERIMENTAL
Intervention: DM removal before trephination (group 1; 43 eyes)
Number of subjects: 83
Study 32246302 — intervention group
Group type: COMPARATOR
Intervention: DM removal after trephination (group 2; 40 eyes)
Number of subjects: 83
Study 32246302 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of roundness and precision of donor button cuts
Number of subjects: 83
Study 35234569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (doubled dosing interval and discontinued etanercept after 6 months)
Number of subjects: 160
Study 35234569 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued standard dose for 6 months and then doubled dosing interval)
Number of subjects: 160
Study 35234569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 33526504 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy using virtual reality (VR)
Number of subjects: 45
Study 33526504 — intervention group
Group type: COMPARATOR
Intervention: Active control using a laptop computer or physical items
Number of subjects: 45
Study 33526504 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 45
Study 33526504 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 45
Study 33559381 — intervention group
Group type: EXPERIMENTAL
Intervention: High schizotypy group
Number of subjects: 80
Study 33559381 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 80
Study 33559381 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexical measures
Number of subjects: 80
Study 35048253 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage Therapy (MT)
Number of subjects: 160
Study 35048253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 160
Study 35048253 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 160
Study 35048253 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 160
Study 32056126 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model (faster RCNN) for automatic detection of aneurysms
Number of subjects: 311
Study 34980119 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air cleaners
Number of subjects: 75
Study 32490948 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational stress assessment using the demand‐control model proposed by Karasek.
Number of subjects: 126
Study 36136603 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 9
Study 36136603 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 9
Study 36136603 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Exercise (CE)
Number of subjects: 9
Study 35630050 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm Gallium−Aluminum−Arsenide diode laser (0.8 W output power, energy density of 5.33 J/mm2, for 30 s)
Number of subjects: 30
Study 35630050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (0.75 W power, 75 mJ pulse energy, pulse repetition rate of 10 Hz, 5 J/mm2 fluency, average exposure time of 30 s)
Number of subjects: 30
Study 35630050 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no treatment)
Number of subjects: 30
Study 34338883 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (HP; 24.3 energy% protein)
Number of subjects: 34
Study 34338883 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (NP; 18.6 energy% protein)
Number of subjects: 34
Study 32933575 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat group
Number of subjects: 0
Study 32933575 — intervention group
Group type: COMPARATOR
Intervention: Leaflet group
Number of subjects: 0
Study 32933575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 35291006 — intervention group
Group type: EXPERIMENTAL
Intervention: Snare-assisted POEM
Number of subjects: 75
Study 35291006 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic knife (HookKnife)
Number of subjects: 75
Study 32382137 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram/memantine combination treatment
Number of subjects: 0
Study 32382137 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 0
Study 33040817 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with ropivacaine (Group B)
Number of subjects: 90
Study 33040817 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (Group A)
Number of subjects: 90
Study 34311755 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxiang Zhengqi (HXZQ) oral liquid
Number of subjects: 212
Study 34311755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 32186926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal Model-Based Psychiatric Nursing Approach (7 one to one sessions)
Number of subjects: 27
Study 32186926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 27
Study 34130243 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (100 mg)
Number of subjects: 12
Study 34130243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32971005 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy (1500 mg IV every 4 weeks)
Number of subjects: 1032
Study 32971005 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (1500 mg durvalumab + 75 mg tremelimumab IV every 4 weeks for up to four doses, followed by durvalumab maintenance)
Number of subjects: 1032
Study 32971005 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine plus cisplatin or gemcitabine plus carboplatin for up to six cycles)
Number of subjects: 1032
Study 32971005 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 1032
Study 32971005 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 1032
Study 32971005 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1032
Study 616026366 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% - Timolol 0.5% (Combigan)
Number of subjects: 62
Study 616026366 — intervention group
Group type: COMPARATOR
Intervention: Baseline elevated IOP
Number of subjects: 62
Study 33031829 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI 100/62.5/25 μg
Number of subjects: 10355
Study 33031829 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 100/25 μg
Number of subjects: 10355
Study 33031829 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25 μg
Number of subjects: 10355
Study 35909376 — intervention group
Group type: EXPERIMENTAL
Intervention: Braided absorbable polyglactin suture
Number of subjects: 40
Study 35909376 — intervention group
Group type: COMPARATOR
Intervention: Braided nonabsorbable polyethylene terephthalate suture
Number of subjects: 40
Study 33950929 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver needle treatment group
Number of subjects: 0
Study 33950929 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine treatment group
Number of subjects: 0
Study 34222105 — intervention group
Group type: COMPARATOR
Intervention: Titanium prosthesis
Number of subjects: 106
Study 34222105 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycel prosthesis
Number of subjects: 106
Study 33287815 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring intervention
Number of subjects: 12
Study 33287815 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups and structured interviews
Number of subjects: 12
Study 35216619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) plus double-pigtail plastic stent (DPS)
Number of subjects: 84
Study 35216619 — intervention group
Group type: COMPARATOR
Intervention: Lumen-apposing metal stent (LAMS)
Number of subjects: 84
Study 32299853 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded breathing using an inspiratory threshold load
Number of subjects: 40
Study 32299853 — intervention group
Group type: COMPARATOR
Intervention: Unloaded breathing
Number of subjects: 40
Study 32949087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (cis-RT)
Number of subjects: 546
Study 32949087 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (cetux-RT)
Number of subjects: 546
Study 33082181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-delivered educational videos on physical activity, blood pressure, diet, medications, smoking, and general health (n=220)
Number of subjects: 330
Study 33082181 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra video on CPR (substudy, randomised 1:1)
Number of subjects: 330
Study 33082181 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=110)
Number of subjects: 330
Study 33082181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-delivered educational videos (n=220)
Number of subjects: 330
Study 36294349 — intervention group
Group type: EXPERIMENTAL
Intervention: Denneroll™ thoracic traction orthosis (DTTO)
Number of subjects: 80
Study 36294349 — intervention group
Group type: COMPARATOR
Intervention: Control group (multimodal program without DTTO)
Number of subjects: 80
Study 33944578 — intervention group
Group type: EXPERIMENTAL
Intervention: XTJ2 conidial suspension (1×10^5 spores/mL)
Number of subjects: 15
Study 33944578 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 15
Study 36368479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric derisomaltose (1000 mg single dose)
Number of subjects: 746
Study 36368479 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate (325 mg tablet, 1–3 times daily)
Number of subjects: 746
Study 33384827 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-fixed oral appliance (OA)
Number of subjects: 15
Study 33384827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed oral appliance (OA)
Number of subjects: 15
Study 33384827 — intervention group
Group type: COMPARATOR
Intervention: Baseline (without OA)
Number of subjects: 15
Study 35893907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (25,000 IU per day over 4 consecutive days, followed by 25,000 IU per week up to 6 weeks)
Number of subjects: 50
Study 35893907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 50
Study 35893907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33820784 — intervention group
Group type: EXPERIMENTAL
Intervention: AMBIsome Therapy Induction Optimisation (AMBITION) Trial
Number of subjects: 0
Study 33234528 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated WASH and nutrition intervention
Number of subjects: 0
Study 35582957 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 222
Study 32778876 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg daily)
Number of subjects: 19114
Study 32778876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 34038529 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-intensified antenatal care (I-ANC)
Number of subjects: 660
Study 34038529 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (S-ANC)
Number of subjects: 660
Study 32972066 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl alcohol group
Number of subjects: 60
Study 32972066 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane group
Number of subjects: 60